Dermata Therapeutics Inc

NASDAQ:DRMAUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Dermata Therapeutics, Inc. is a late-stage medical dermatology company. The Company is focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, DMT310 and DMT410, both incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its lead product candidate, DMT310, is intended to utilize its Spongilla technology for once weekly treatment of a variety of skin diseases, with its initial focus being the treatment of acne vulgaris, which has a United States market size of approximately 50 million patients. Its second product candidate utilizing its Spongilla technology is DMT410, its combination treatment. DMT410 is intended to consist of one treatment of its proprietary sponge powder followed by one topical application of botulinum toxin for delivery into the dermis.

Contact Information

Headquarters

3525 Del Mar Heights Rd., #322SAN DIEGO, CA, United States 92130

Phone

858-223-0882

Fax

302-636-5454

Executives

Chairman of the Board, President, Chief Executive Officer

Gerald Proehl

Chief Financial Officer, Senior Vice President

Kyri Van Hoose

Senior Vice President - Regulatory Affairs and Quality Assurance

Maria Bedoya Toro Munera

Senior Vice President, Chief Development Officer

Christopher Nardo

Lead Independent Director

David Hale